Search - tctmd.com

Displaying 41 - 60 of 457

Sort: Relevancy | Date

Presentation TCT 2024

TCT 638: Impact of Acute Hemodynamic Effects on Myocardial Remodeling and Mid-Term Durability After Transcatheter Edge-to-Edge Repair (TEER) of Mitral Regurgitation Using PASCAL®

Presenter: Tobias Geisler

October 28, 2024

Presentation TCT 2024

TCT 949: Long-term Mechanical Durability of Surgical Aortic Valves: A 2 Billion Cycle In Vitro Study

Presenter: Jae Hyun Jae

October 28, 2024

News Daily News

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

Caitlin E. Cox

September 12, 2024

News Features

Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question

L.A. McKeown

August 09, 2024

News Daily News

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Yael L. Maxwell

July 22, 2024

News Daily News

Knowns and Unknowns in Subclinical Aortic Valve Thrombosis

Caitlin E. Cox

June 21, 2024

News Conference News NY Valves 2024

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

Todd Neale

June 14, 2024

News Conference News NY Valves 2024

National Data Point to Soaring TAVI Rates in Patients Under 65

Michael O'Riordan

June 14, 2024

Presentation NY Valves 2024

TAVR Durability: What Do We Know So Far?

Presenter: Helene Eltchaninoff

June 07, 2024

Presentation NY Valves 2024

Importance of Valve Durability and Avoiding Patient-Prosthesis Mismatch

Presenter: Samir R. Kapadia

June 06, 2024

Presentation NY Valves 2024

Which endpoints and definitions matter for assessment of bioprosthetic valve durability following TAVR?

Presenter: Philippe Pibarot

June 06, 2024

Presentation NY Valves 2024

You are Both Wrong, Engineers Hold the Key to Our Future and the Best Valve Design is Yet to be Found

Presenter: Ajit P. Yoganathan

June 06, 2024

Presentation NY Valves 2024

SAVR Will Have a Longer Lasting Durability Than TAVR

Presenter: Stephan Windecker

June 06, 2024

Presentation NY Valves 2024

TAVR Will Have a Longer Lasting Durability Than SAVR

Presenter: Michael J. Reardon

June 06, 2024

Presentation NY Valves 2024

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

Presenter: Mark Lebehn

June 06, 2024

Presentation NY Valves 2024

Cases 1/2 : TAVR at 8 Years and SVD at 2 Years

Presenter: Guillaume Bonnet

June 06, 2024

Presentation NY Valves 2024

Subclinical Leaflet Thrombosis : Identification, Incidence and Importance

Presenter: Raj Makkar

June 06, 2024

Presentation NY Valves 2024

Definitions of Bioprosthetic Valve Dysfunction and Failure: Is There a Common Definition?

Presenter: Philippe Pibarot

June 06, 2024

News Conference News NY Valves 2024

Reassuring 5-Year Outcomes for Sapien-Treated TAVI Patients With Small Annuli

Michael O'Riordan

June 05, 2024

Presentation NY Valves 2024

Options for a Lifetime and Long-Term Durability

Presenter: Ole De Backer

June 05, 2024

Advertisement

TCT 638: Impact of Acute Hemodynamic Effects on Myocardial Remodeling and Mid-Term Durability After Transcatheter Edge-to-Edge Repair (TEER) of Mitral Regurgitation Using PASCAL®

TCT 949: Long-term Mechanical Durability of Surgical Aortic Valves: A 2 Billion Cycle In Vitro Study

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Knowns and Unknowns in Subclinical Aortic Valve Thrombosis

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

National Data Point to Soaring TAVI Rates in Patients Under 65

TAVR Durability: What Do We Know So Far?

Importance of Valve Durability and Avoiding Patient-Prosthesis Mismatch

Which endpoints and definitions matter for assessment of bioprosthetic valve durability following TAVR?

You are Both Wrong, Engineers Hold the Key to Our Future and the Best Valve Design is Yet to be Found

SAVR Will Have a Longer Lasting Durability Than TAVR

TAVR Will Have a Longer Lasting Durability Than SAVR

Cases 3/4 : SAVR at 10 Years and SVD at 2 Years: Echo and Clinical

Cases 1/2 : TAVR at 8 Years and SVD at 2 Years

Subclinical Leaflet Thrombosis : Identification, Incidence and Importance

Definitions of Bioprosthetic Valve Dysfunction and Failure: Is There a Common Definition?

Reassuring 5-Year Outcomes for Sapien-Treated TAVI Patients With Small Annuli

Options for a Lifetime and Long-Term Durability

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content